Overview

Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
0
Participant gender:
All
Summary
This is a two part study. In the first part, the pharmacokinetic profile of Epigallocatechin-3-gallate (EGCG) in normal human volunteers given a single oral dose will be determined to set the dose for the second part of the study. In the second part of this study, lung biopsy fragments and urine samples from patients with interstitial lung disease treated with EGCG will be evaluated in biochemical assays and compared to samples from untreated control patients.
Phase:
Early Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Epigallocatechin gallate
Criteria
Inclusion Criteria:

- Part 1: healthy volunteers

- Part 2:

- study will consist of patients presenting to the UCSF interstitial lung disease (ILD)
outpatient clinic with imaging indicative of lung fibrosis but of uncertain
classification, and who are willing to take EGCG for a minimum of 2 weeks prior to
surgery.

Exclusion Criteria:

- co-morbidities affect hepatic function, such as HCV infection, cirrhosis, or

- using drugs with significant hepatic toxicities